Abbott Laboratories (ABT) Receives "Overweight" Rating from Barclays PLC

Marco Green
October 21, 2017

Expedia, Inc. (NASDAQ:EXPE) [Trend Analysis] share price swings at $153.40 with percentage change of 0.74% in most recent trading session. During the same period in the previous year, the company posted $0.54 earnings per share.

Several other research firms also recently commented on ABT. Villere ST Denis J & Co. Stifel Nicolaus maintained it with "Buy" rating and $63.0 target in Thursday, October 19 report. Citigroup maintained the shares of MBLY in report on Friday, August 7 with "Buy" rating. BMO Capital Markets maintained it with "Hold" rating and $53.0 target in Monday, October 2 report. The firm earned "Overweight" rating on Wednesday, October 7 by Barclays Capital. Three months ago, analysts assigned ABT a 4.41 rating, which implies that analysts have become more pessimistic about the outlook for the stock over the next year. The company now has an average rating of Buy and an average target price of $56.81.

Shares of Abbott Laboratories (ABT) opened at 56.00 on Friday. 5,528,681 shares of the company traded hands. The firm has a market cap of $97.30 billion, a price-to-earnings ratio of 78.43 and a beta of 1.06.

Moving toward other technical indicators, stock is wondering in considerable region as it has 20 days moving average of 3.75% and struggles for 50 days moving average of buoyant run is 8.04%. The stock appeared $56.60 above its 52-week highs and is up 2.36% for the last five trades. Abbott Laboratories (NYSE:ABT) has risen 15.90% since October 20, 2016 and is uptrending. The healthcare product maker reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.01. Abbott Laboratories had a return on equity of 15.46% and a net margin of 6.61%. The company had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Investors who are keeping close eye on the stock of Abbott Laboratories (NYSE:ABT) established that the company was able to keep return on investment at - in the trailing twelve month while Reuters data showed that industry's average stands at 4.62 and sector's optimum level is 10.90. Abbott Laboratories's revenue for the quarter was up 28.8% on a year-over-year basis. Equities analysts anticipate that Abbott Laboratories will post $2.50 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was illegally copied and republished in violation of global trademark and copyright laws. The original version of this piece can be accessed at https://weekherald.com/2017/10/20/abbott-laboratories-abt-receives-overweight-rating-from-barclays-plc.html. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories's payout ratio is 83.47%. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Insiders contain to comply with strict disclosure requirements with regard to the sale or purchase of the shares of their company. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sharon J. Bracken sold 2,000 shares of the company's stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $50.00, for a total value of $750,000.00. After a recent check, it is observed that the insiders for the firm now own 0.50% shares. The America First Investment Advisors Llc holds 251,330 shares with $12.22M value, up from 244,872 last quarter. The Michigan-based Sigma Investment Counselors Inc has invested 0.1% in the stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Among holders that decreased their positions, 76 sold out of the stock Abbott Laboratories. A statistical measure of the dispersion of returns (volatility) for ABT producing salvation in Investors mouth, it has week volatility of 1.46% and for the month booked as 1.41%. State Street Corp grew its holdings in shares of Abbott Laboratories by 18.9% during the 1st quarter. Meyer Handelman Co. increased its stake in Abbott Laboratories by 5.1% during the first quarter. Moloney Securities Asset Management LLC now owns 26,280 shares of the healthcare product maker's stock worth $1,167,000 after acquiring an additional 1,517 shares during the last quarter. Whittier Trust Co. now owns 401,048 shares of the healthcare product maker's stock worth $17,807,000 after purchasing an additional 6,751 shares in the last quarter. Waldron LP boosted its holdings in Abbott Laboratories by 41.0% during the first quarter. Lucas Cap Management accumulated 95,340 shares or 1.86% of the stock. Institutional investors own 71.45% of the company's stock.

Abbott Laboratories, launched on March 6, 1900, is involved in the discovery, development, manufacture and sale of a range of healthcare products. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the worldwide sales of a line of branded generic pharmaceutical products.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER